- Home
- / Kadimastem
Kadimastem
Stock Price
₪9.3
2024-10-29
Market Capitalization
₪3.9 B
2024-10-29
Kadimastem Summary
Company Summary
- Overview
- Kadimastem is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells (hESCs). It aims to treat neurodegenerative diseases such as amyotrophic lateral sclerosis and diabetes.
- Type
- Public
- Status
- Active
- Founded
- 2009
- HQ
- Ness Ziona, IL | view all locations
- Website
- https://www.kadimastem.com/
- Cybersecurity rating
Table of Contents
Key People
Ronen Twito, Chairman of the Board
Kfir Molakandov, Director of Diabetes and Innovation
Ariel Revel, Director of Medical Affairs
LocationsView all
1 location detected
Ness Ziona, Center District HQ
Israel
Weizmann/Science Park
Kadimastem Financials
Summary Financials
- Net income (Q2, 2025)
- (₪40.3M)
- Cash (Q2, 2025)
- ₪1.0M
- EBIT (Q2, 2025)
- (₪4.9M)
- Enterprise value
- $3.9B